Annual Cash & Cash Equivalents
$3.30 B
+$74.00 M+2.29%
December 31, 2024
Summary
- As of February 25, 2025, TEVA annual cash & cash equivalents is $3.30 billion, with the most recent change of +$74.00 million (+2.29%) on December 31, 2024.
- During the last 3 years, TEVA annual cash & cash equivalents has risen by +$1.14 billion (+52.42%).
- TEVA annual cash & cash equivalents is now -52.49% below its all-time high of $6.95 billion, reached on December 31, 2015.
Performance
TEVA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.30 B
-$19.00 M-0.57%
December 31, 2024
Summary
- As of February 25, 2025, TEVA quarterly cash and cash equivalents is $3.30 billion, with the most recent change of -$19.00 million (-0.57%) on December 31, 2024.
- Over the past year, TEVA quarterly cash and cash equivalents has stayed the same.
- TEVA quarterly cash and cash equivalents is now -52.75% below its all-time high of $6.98 billion, reached on June 30, 2016.
Performance
TEVA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TEVA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2.3% | 0.0% |
| 3 y3 years | +52.4% | 0.0% |
| 5 y5 years | +67.1% | 0.0% |
TEVA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +52.4% | -0.6% | +60.4% |
| 5 y | 5-year | at high | +67.1% | -0.6% | +89.3% |
| alltime | all time | -52.5% | >+9999.0% | -52.8% | >+9999.0% |
Teva Pharmaceutical Industries Limited Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $3.30 B(+2.3%) | $3.30 B(-0.6%) |
| Sep 2024 | - | $3.32 B(+47.0%) |
| Jun 2024 | - | $2.26 B(-24.5%) |
| Mar 2024 | - | $2.99 B(-7.3%) |
| Dec 2023 | $3.23 B(+15.2%) | $3.23 B(+43.4%) |
| Sep 2023 | - | $2.25 B(-15.7%) |
| Jun 2023 | - | $2.67 B(+24.5%) |
| Mar 2023 | - | $2.14 B(-23.5%) |
| Dec 2022 | $2.80 B(+29.4%) | $2.80 B(+25.9%) |
| Sep 2022 | - | $2.23 B(+8.1%) |
| Jun 2022 | - | $2.06 B(-5.4%) |
| Mar 2022 | - | $2.17 B(+0.5%) |
| Dec 2021 | $2.17 B(-0.6%) | $2.17 B(+5.9%) |
| Sep 2021 | - | $2.04 B(-16.1%) |
| Jun 2021 | - | $2.44 B(+39.8%) |
| Mar 2021 | - | $1.74 B(-19.9%) |
| Dec 2020 | $2.18 B(+10.2%) | $2.18 B(+19.2%) |
| Sep 2020 | - | $1.83 B(-23.9%) |
| Jun 2020 | - | $2.40 B(+33.1%) |
| Mar 2020 | - | $1.80 B(-8.7%) |
| Dec 2019 | $1.98 B(+10.8%) | $1.98 B(+59.1%) |
| Sep 2019 | - | $1.24 B(-42.7%) |
| Jun 2019 | - | $2.17 B(+9.7%) |
| Mar 2019 | - | $1.97 B(+10.7%) |
| Dec 2018 | $1.78 B(+85.0%) | $1.78 B(-5.0%) |
| Sep 2018 | - | $1.88 B(+0.8%) |
| Jun 2018 | - | $1.86 B(+31.2%) |
| Mar 2018 | - | $1.42 B(+47.2%) |
| Dec 2017 | $963.00 M(-2.5%) | $963.00 M(+41.6%) |
| Sep 2017 | - | $680.00 M(+13.5%) |
| Jun 2017 | - | $599.00 M(-33.4%) |
| Mar 2017 | - | $900.00 M(-8.9%) |
| Dec 2016 | $988.00 M(-85.8%) | $988.00 M(-36.5%) |
| Sep 2016 | - | $1.56 B(-77.7%) |
| Jun 2016 | - | $6.98 B(+17.1%) |
| Mar 2016 | - | $5.96 B(-14.1%) |
| Dec 2015 | $6.95 B(+212.0%) | $6.95 B(+648.5%) |
| Sep 2015 | - | $928.00 M(-13.1%) |
| Jun 2015 | - | $1.07 B(-68.6%) |
| Mar 2015 | - | $3.40 B(+52.6%) |
| Dec 2014 | $2.23 B(+114.5%) | $2.23 B(+51.1%) |
| Sep 2014 | - | $1.47 B(+55.2%) |
| Jun 2014 | - | $949.00 M(+5.3%) |
| Mar 2014 | - | $901.00 M(-13.2%) |
| Dec 2013 | $1.04 B(-63.9%) | $1.04 B(-9.6%) |
| Sep 2013 | - | $1.15 B(-7.8%) |
| Jun 2013 | - | $1.25 B(-10.7%) |
| Mar 2013 | - | $1.39 B(-51.6%) |
| Dec 2012 | $2.88 B(+162.7%) | $2.88 B(+101.0%) |
| Sep 2012 | - | $1.43 B(+20.5%) |
| Jun 2012 | - | $1.19 B(+11.9%) |
| Mar 2012 | - | $1.06 B(-3.1%) |
| Dec 2011 | $1.10 B(-12.2%) | $1.10 B(+1.0%) |
| Sep 2011 | - | $1.08 B(-4.7%) |
| Jun 2011 | - | $1.14 B(+58.0%) |
| Mar 2011 | - | $721.00 M(-42.2%) |
| Dec 2010 | $1.25 B | $1.25 B(+33.5%) |
| Sep 2010 | - | $935.00 M(-80.7%) |
| Jun 2010 | - | $4.85 B(+106.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2010 | - | $2.36 B(+18.1%) |
| Dec 2009 | $2.00 B(+7.6%) | $2.00 B(+24.8%) |
| Sep 2009 | - | $1.60 B(-9.3%) |
| Jun 2009 | - | $1.76 B(-25.1%) |
| Mar 2009 | - | $2.35 B(+26.8%) |
| Dec 2008 | $1.85 B(+24.6%) | $1.85 B(-35.0%) |
| Sep 2008 | - | $2.85 B(+14.9%) |
| Jun 2008 | - | $2.48 B(-1.0%) |
| Mar 2008 | - | $2.51 B(+68.6%) |
| Dec 2007 | $1.49 B(+11.7%) | $1.49 B(-1.3%) |
| Sep 2007 | - | $1.51 B(-6.8%) |
| Jun 2007 | - | $1.62 B(+37.6%) |
| Mar 2007 | - | $1.18 B(-11.7%) |
| Dec 2006 | $1.33 B(+4.4%) | $1.33 B(+59.8%) |
| Sep 2006 | - | $833.50 M(-3.4%) |
| Jun 2006 | - | $863.10 M(-10.9%) |
| Mar 2006 | - | $968.30 M(-24.1%) |
| Dec 2005 | $1.28 B(+62.8%) | $1.28 B(+81.5%) |
| Sep 2005 | - | $703.10 M(-15.7%) |
| Jun 2005 | - | $834.30 M(+18.9%) |
| Mar 2005 | - | $701.60 M(-10.5%) |
| Dec 2004 | $784.00 M(-25.8%) | $784.00 M(-14.6%) |
| Sep 2004 | - | $918.10 M(+29.0%) |
| Jun 2004 | - | $711.70 M(+0.2%) |
| Mar 2004 | - | $710.00 M(-32.8%) |
| Dec 2003 | $1.06 B(+30.5%) | $1.06 B(+32.1%) |
| Sep 2003 | - | $800.10 M(-9.0%) |
| Jun 2003 | - | $879.30 M(-5.4%) |
| Mar 2003 | - | $929.40 M(+14.8%) |
| Dec 2002 | $809.90 M(+5.3%) | $809.90 M(+117.8%) |
| Sep 2002 | - | $371.80 M(-35.5%) |
| Jun 2002 | - | $576.30 M(-11.9%) |
| Mar 2002 | - | $653.80 M(-15.0%) |
| Dec 2001 | $768.92 M(+82.8%) | $768.92 M(-4.3%) |
| Sep 2001 | - | $803.30 M(+139.0%) |
| Jun 2001 | - | $336.09 M(-4.8%) |
| Mar 2001 | - | $353.06 M(-16.1%) |
| Dec 2000 | $420.63 M(+445.0%) | $420.63 M(+350.3%) |
| Jun 2000 | - | $93.41 M(-13.7%) |
| Mar 2000 | - | $108.25 M(+40.3%) |
| Dec 1999 | $77.18 M(+63.9%) | $77.18 M(-35.9%) |
| Sep 1999 | - | $120.40 M(+115.4%) |
| Jun 1999 | - | $55.90 M(-19.9%) |
| Mar 1999 | - | $69.80 M(+48.2%) |
| Dec 1998 | $47.10 M(-7.5%) | $47.10 M(-15.6%) |
| Sep 1998 | - | $55.80 M(-41.4%) |
| Jun 1998 | - | $95.30 M(+56.5%) |
| Mar 1998 | - | $60.90 M(+19.6%) |
| Dec 1997 | $50.90 M(-16.8%) | $50.90 M(-16.8%) |
| Dec 1996 | $61.20 M(-5.7%) | $61.20 M(-5.7%) |
| Dec 1995 | $64.90 M(+53.1%) | $64.90 M(+53.1%) |
| Dec 1994 | $42.40 M(+6.3%) | $42.40 M(+6.3%) |
| Dec 1993 | $39.90 M(+189.1%) | $39.90 M(+189.1%) |
| Dec 1992 | $13.80 M(+74.7%) | $13.80 M(+74.7%) |
| Dec 1991 | $7.90 M(-48.7%) | $7.90 M(-48.7%) |
| Dec 1990 | $15.40 M(+234.8%) | $15.40 M(+234.8%) |
| Dec 1989 | $4.60 M(-64.9%) | $4.60 M(-64.9%) |
| Dec 1988 | $13.10 M(-17.6%) | $13.10 M(-17.6%) |
| Mar 1987 | $15.90 M(-29.0%) | $15.90 M(-29.0%) |
| Mar 1986 | $22.40 M | $22.40 M |
FAQ
- What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents year-on-year change?
- What is Teva Pharmaceutical Industries Limited quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited quarterly cash and cash equivalents year-on-year change?
What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents?
The current annual cash & cash equivalents of TEVA is $3.30 B
What is the all time high annual cash & cash equivalents for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high annual cash & cash equivalents is $6.95 B
What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents year-on-year change?
Over the past year, TEVA annual cash & cash equivalents has changed by +$74.00 M (+2.29%)
What is Teva Pharmaceutical Industries Limited quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TEVA is $3.30 B
What is the all time high quarterly cash and cash equivalents for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high quarterly cash and cash equivalents is $6.98 B
What is Teva Pharmaceutical Industries Limited quarterly cash and cash equivalents year-on-year change?
Over the past year, TEVA quarterly cash and cash equivalents has changed by $0.00 (0.00%)